I'm an image

“2020 is going to be my year.” – Zoom, probably.

Hey there carnivores,


The markets were mixed on Monday, but closed out a STRONG August… 


Today we’re talking Zoom’s strong showing last quarter.


Keep raging,

Jeff & Jason


I'm an image

“Hi, who just joined?”


Absolutely nobody…

Zoom: “Idk, 2020 is a pretty good year, tbh.”


Zoom reported earnings on Monday, and let’s just say the coronavirus has been good to the video conferencing company.


Revenue shot through the roof, coming in four times higher than Q2 last year. The $663.5M blew analysts estimate of $500M out of the motherf*ckin’ water. EPS of 92 cents was more than double the projected 45 cents. So, yeah, you could say Zoom had a better Monday than you.


A forward-looking statement


CEO Eric Yaun is getting cocky about the future. And for good reason.


Previously, the company projected that its annual revenue would come in around $1.8B. That figure was updated yesterday to $2.39B for the year ending in January. 


All this, combined with a hearty helping of blind optimism, led the stock to go HAM during after-hours trading. While the 8.63% gain during trading was nice, the 23.34% increase after the bell was even better.


The bottom line…


COVID and Zoom go together better than lamb and tuna fish. 

Millions of cubicle warriors have been forced to work from home, with their companies adopting Zoom. The company now has 370k business customers of 10+ employees utilizing its services. Sucks to suck, Skype. 


An analyst from DA Davidson (presumably the brother of Harley) thought that Zoom’s Q1 was the best quarter for a software company… of all time. Zoom somehow one-upped itself in Q2.


I'm an image

☑️Don’t call it a comeback. August stock market returns proved to be the best in 34 years, with companies of all shapes and sizes getting in on the action. Tech stocks saw huge gains, but “reopening stocks” also surged.


Norwegian Cruise Lines and Delta both gained 25% in August, while Royal Caribbean rose 40%. Andrew Slimmon, a PM at Morgan Stanley, noted that “it’s like the riskier the stock, the better it did.”


☑️McDouble trouble. McDonald’s offers refunds, but it’s former CEO does not. Steve Easterbrook has refused to give Ronald and the gang back any severance after he was terminated for having a consensual relationship with an employee. The company claims Easterbrook lied to investigators and the board when they launched an investigation into his affairs in the summer of 2019.


Easterbrook already tried getting the suit dismissed, claiming that Mickey D’s investigation wasn’t thorough enough. So you don’t want to pay your former employer back because they didn’t find enough dirt on you? What’s the angle here, Steve?

tbh, it sounds like the whole place was running like a brothel as other reports came out last week, citing a lack of action by HR when it received complaints about executives’ behavior. It’s probably not a coincidence that McDonald’s fired Chief of HR David Fairhurst shortly after Easterbrook on claims that he himself was making women uncomfortable. This is why I’ve always been a Wendy’s guy…


☑️Get your peanuts. Nestle is continuing its pivot away from chocolate milk and into healthcare. The packaged-food giant purchased Aimmune Therapeutics, which earlier this year won approval for a drug to treat peanut allergies. Take that, legume.

The all-cash deal valued Aimmune at $2.6B, including debt. Nestle took a 25% stake in Aimmune back in 2016 and has actually developed a healthy health-sciences business over the past few decades.


Nestle seems to be getting in right in time for mass-distribution. Aimmune got approval from the FDA in January and plans to charge *only* $890 per month for the drug. That’s right, $10k per year to eat peanuts.


☑️Drug dealin’ just to get by. Move over Nestle, Bayer’s out here making some dope boy moves as well. The drug manufacturer purchased online vitamin and health care company Care/Of for $225M.


The deal includes a 70% stake in Care/Of with an option to buy the rest of the four-year-old company down the road. Exact terms were not disclosed.


This is Bayer’s second deal of the month as it bought women’s health care company Kandy Therapeutics for $875M. Digital health businesses during a pandemic seem to be a good investment. If only we had some stimulus money to buy some shares with…

Author: Jeff Bishop

One of the best traders anywhere, over the past 20 years Jeff’s made multi-millions trading stocks, ETFs, and options. He is renowned as an incredible trader with a deep insight and a sensitive pulse on the markets and the economy. Jeff Bishop is CEO and Co-Founder of RagingBull.com.

Even greater than his prowess as a trader is his skill and passion in teaching others how to trade and rake in profits while managing risk.

Learn More

Leave your comment